Emerging data from heart failure trials: Clinical application

Gary Francis

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


The interest in treatment for heart failure is shifting away from traditional inotropic therapy towards drugs that modulate neuroendocrine activity. Data are presented on the assessment of endothelin receptor blockers, as well as angiotensin II type 1 receptor blockers versus angiotensin-converting enzyme inhibitors in heart failure. Ongoing studies assessing beta-blockers and new calcium channel blockers in heart failure are described.

Original languageEnglish (US)
Pages (from-to)27D-29D
JournalCanadian Journal of Cardiology
Issue numberSUPPL. D
StatePublished - 1998


  • Clinical trials
  • Heart failure


Dive into the research topics of 'Emerging data from heart failure trials: Clinical application'. Together they form a unique fingerprint.

Cite this